Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients

• Sanofi SA (NASDAQ:SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.
• Sarclisa combined with carfilzomib and dexamethasone (Kd) demonstrated a median progression-free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone. 
• Following the FDA recommendations on censoring rules, the analysis showed an mPFS of 41.7 months for Sarclisa combination therapy compared to 20.8 months in patients treated with Kd alone.
• The time to next treatment for patients treated with Sarclisa combination therapy was 44.9 months versus those treated with Kd alone at 25 months.
• The safety and tolerability of Sarclisa observed in this analysis were consistent with the safety profile of Sarclisa in other clinical trials, with no new safety signals observed. 
• Price Action: SNY shares are up 0.74% at $52.42 during the market session on the last check Monday.